top of page

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

IGC Pharma, Inc. Common Stock (NY:IGC)

0.2932 -0.0041 (-1.38%)

Streaming Delayed Price Updated: 10:07 AM EST, Dec 30, 2025 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	68,300
Open	0.2980
Bid (Size)	0.2926 (5,400)
Ask (Size)	0.2938 (600)
Prev. Close	0.2973
Today's Range	0.2926 - 0.2980
52wk Range	0.2525 - 0.4985
Shares Outstanding	49,784,017
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

IGC Pharma Secures New U.S. Patent as Pharmaceutical Cannabinoids Gain Regulatory Momentum

December 19, 2025

Via ACCESS Newswire

IGC Pharma Positions as a Singular Beneficiary of Emerging Federal Momentum Toward Schedule III Cannabinoid Medicines

December 15, 2025

Via ACCESS Newswire

Performance

YTD	-17.9%	-17.9%
1 Month	-6.9%	-6.9%
3 Month	-30.2%	-30.2%
6 Month	-4.2%	-4.2%
1 Year	-17.2%	-17.2%

More News

IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q2 results. We believe more positive clinical data and progress in 2025/26 to be strong catalysts for stock. Raising P/T to $4.75."

December 10, 2025

Via ACCESS Newswire

IGC Pharma Reports 65% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer's Agitation Trial

December 09, 2025

Via ACCESS Newswire

IGC Pharma Announces Publication of Landmark Caregiver Book on Alzheimer's Disease

December 02, 2025

Via ACCESS Newswire

IGC Pharma Leverages MINT-AD to Identify Socioeconomic Risk Factors Driving Alzheimer's and Aging Trends

November 25, 2025

Via ACCESS Newswire

IGC Pharma Reports Accelerated Q2 Progress and Strengthened Financial Focus: CALMA Trial Passes 50% Enrollment Milestone, Strategic Divestiture Optimizes Capital

November 17, 2025

Via ACCESS Newswire

USPTO Grants IGC Pharma Patent Covering IGC-AD1 for Novel Composition Targeting Alzheimer's Disease and Central Nervous System Disorders

November 13, 2025

Via ACCESS Newswire

IGC Pharma to Host Mid-Year Fiscal 2026 Shareholder Update Call on November 17, 2025

November 10, 2025

Via ACCESS Newswire

IGC Pharma Expands AI-Powered Drug Discovery In-Silico Pipeline

November 03, 2025

Via ACCESS Newswire

IGC Pharma Advances to Semi-Finals in the Alzheimer's Insights AI Prize with "AHA: Agentic Harmonization Assistant"

October 22, 2025

Via ACCESS Newswire

IGC Pharma Expands Phase 2 CALMA Clinical Trial to University of South Florida's Department of Psychiatry and Behavioral Neurosciences

October 14, 2025

Via ACCESS Newswire

IGC Pharma Announces Results of 2025 Annual Meeting of Stockholders

October 10, 2025

Via ACCESS Newswire

IGC Pharma's Preclinical Data for IGC-1C: New Drug Candidate Potentially Disrupts a Foundational Mechanism of Alzheimer's Disease

October 07, 2025

Via ACCESS Newswire

IGC Pharma Adds Ichor Research as New Site for CALMA Phase 2 Alzheimer's Trial

September 29, 2025

Via ACCESS Newswire

IGC Pharma Announces Preclinical Data Demonstrating TGR-63’s Dual Action on Alzheimer’s Pathology

September 24, 2025

Via ACCESS Newswire

IGC Pharma Reports 50% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer's Agitation Trial

September 22, 2025

Via ACCESS Newswire

IGC Pharma, Inc. Receives Third Award from the NIA for Excellence in Code Clarity, Reproducibility, and Usability for Alzheimer's Detection

September 09, 2025

Via ACCESS Newswire

IGC Pharma Expands CALMA Phase 2 Trial to Island Health's Royal Jubilee Hospital in Canada

September 02, 2025

Via ACCESS Newswire

Top movers in Thursday's after hours session ↗

August 28, 2025

Via Chartmill

IGC Pharma receives Notice of Allowance for Novel THC Microdose-Based Treatment for Stammering, Stuttering, and Tourette's Syndrome

August 28, 2025

Via ACCESS Newswire

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

August 27, 2025

Via Benzinga

IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q1 results. We believe more positive clinical data and progress in 2025 to be strong catalysts for stock. Raising P/T to $4.50."

August 27, 2025

Via ACCESS Newswire

IGC Pharma Expands CALMA Phase 2 Trial with Site at Lynn Health Science Institute in Oklahoma City

August 25, 2025

Via ACCESS Newswire

IGC Pharma Reports First Quarter Fiscal 2026 Financial Results; Company Accelerates Phase 2 Alzheimer's Trial

August 19, 2025

Via ACCESS Newswire

Frequently Asked Questions

Is IGC Pharma, Inc. Common Stock publicly traded?

Yes, IGC Pharma, Inc. Common Stock is publicly traded.

What exchange does IGC Pharma, Inc. Common Stock trade on?

IGC Pharma, Inc. Common Stock trades on the New York Stock Exchange

What is the ticker symbol for IGC Pharma, Inc. Common Stock?

The ticker symbol for IGC Pharma, Inc. Common Stock is IGC on the New York Stock Exchange

What is the current price of IGC Pharma, Inc. Common Stock?

The current price of IGC Pharma, Inc. Common Stock is 0.2932

When was IGC Pharma, Inc. Common Stock last traded?

The last trade of IGC Pharma, Inc. Common Stock was at 12/30/25 10:07 AM ET

What is the market capitalization of IGC Pharma, Inc. Common Stock?

The market capitalization of IGC Pharma, Inc. Common Stock is 14.60M

How many shares of IGC Pharma, Inc. Common Stock are outstanding?

IGC Pharma, Inc. Common Stock has 15M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

bottom of page